Targeted protein degradation technology provides a potentially powerful therapeutic strategy. Recent advances enabling the generation of patient-derived, <i>ex vivo</i> neuronal models of central nervous system proteinopathies, and the development of small molecules capable of selectively targeting pathological protein conformations, now allow this strategy to be applied to the context of neurodegenerative disease. In this presentation, I will summarize recent findings focused on targeted degradation of tau, a protein implicated in multiple forms of dementia.

Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models

Macromolecular Chemistry: The Second Century

[Author Benefits](https://scimeetings.acs.org/?utm_source=pubs_content_marketing&utm_medium=website&utm_campaign=0320_MCF_NPI_Launch_Spring_Homepage&ref=pubs_content_marketing)

[How to use SciMeetings](https://storage.googleapis.com/dl.morressier.com/acs/SciMeetings-ACSSpring2020-HowToGuide_M3020-Final.pdf)

[Frequently Asked Questions](https://storage.googleapis.com/dl.morressier.com/acs/SciMtng_ACSNMSp2020_FAQ_M3120_Final.pdf)

ACS Spring 2020 National Meeting & Expo

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.